Pharmaceutical
IEX supports pharmaceutical manufacturing operations handling precious and platinum group metals as catalysts.
IEX works with pharmaceutical manufacturers to remove metal impurities from product streams to within regulatory specification and recovering precious metal value from waste streams that may otherwise be written off.
The Challenge
Precious and platinum group metals are widely used as catalysts in pharmaceutical synthesis, particularly in homogeneous catalysis and cross-coupling reactions. These metals drive the chemistry but, generally, do not belong in the final product.
Residual metals in pharmaceutical products are subject to strict elemental impurity limits. Exceeding those limits means batch failure, reprocessing, regulatory risk, and in the worst cases, product recall.
At the same time, the metals being used are valuable. Palladium, platinum, iridium, and ruthenium are costly to procure and are lost into process streams, residues, and waste liquids over time.
Some manufacturers write this off as operational loss, but it does not have to be.
How IEX Helps
IEX's functional scavenger materials are selected and validated for the specific metal, process solvent, and specification involved.
Solutions are designed to perform consistently batch after batch, supporting product release and audit defensibility without disrupting your manufacturing process.
Where metal concentrations in waste streams support it, IEX can design a recovery process alongside the purification solution, converting a disposal cost into a recovery return.
Relevant Solutions
- Critical Impurities: Purification & Impurity Control
- Critical Minerals Recovery
- Recycling & Disposal
Talk to the IEX Technical Team
If you are managing metal impurities in pharmaceutical synthesis or losing precious metal value from your process streams, speak to the IEX technical team.